13F-HR filed by SR ONE CAPITAL MANAGEMENT, LP
SR ONE CAPITAL MANAGEMENT, LP filed this 13F-HR for the quarter ended 2026-09-30, accepted by EDGAR 2026-11-16 21:06:33 UTC, with 17 holding rows worth $1,149,539,649.
- Accession
- 0001012975-26-001062
- Filer
- CIK 1910264
- Filed
- 2026-11-16
- Accepted by EDGAR
- Ingested
- Source
- EDGAR daily index
13F report for Q3 2026
A holdings report, 17 entries on the cover page, a total value of $1,149,539,649 stated on the cover page (in dollars after the unit check, H1), rows summing to $1,149,539,649 with VALUE read as dollars as filed, 13F file number 028-21964. The quarter's positions are built on this report. The resolved quarter.
The information table after summing rows of one CUSIP and put or call (H4), with the CUSIP and issuer name as filed. Values in dollars after the unit check (method).
| Issuer as filed | CUSIP | Class | Amount | Value | Value read as | Type |
|---|---|---|---|---|---|---|
| VERADERMICS INC | 922967104 | COMMON STOCK | 2,080,119 | $252,172,826 | dollars as filed | |
| ADARx Pharmaceuticals, Inc. | 00654F105 | Common Stock, par value $0.0001 per share | 9,936,661 | $198,137,020 | dollars as filed | |
| ZENAS BIOPHARMA INC COM | 98937L105 | Stock | 5,037,854 | $135,870,922 | dollars as filed | |
| CRISPR THERAPEUTICS AG NAMEN AKT | H17182108 | Stock | 2,038,763 | $112,784,369 | dollars as filed | |
| AVALYN PHARMA INC | 05348Y105 | COMMON STOCK | 3,308,649 | $94,263,410 | dollars as filed | |
| Odyssey Therapeutics, Inc. | 67613T104 | COMMON STOCK | 3,794,883 | $84,322,300 | dollars as filed | |
| DESIGN THERAPEUTICS INC | 25056L103 | COM | 6,526,476 | $82,037,803 | dollars as filed | |
| ORIC PHARMACEUTICALS INC | 68622P109 | COM | 4,615,384 | $62,169,223 | dollars as filed | |
| MINERALYS THERAPEUTICS INC | 603170101 | COM | 1,563,966 | $39,302,466 | dollars as filed | |
| KORSANA BIOSCIENCES INC | 23255M303 | COMMON STOCK | 613,915 | $19,645,280 | dollars as filed | |
| MOBIA MED INC | 60705V103 | COMMON STOCK | 1,986,072 | $18,768,380 | dollars as filed | |
| ARS PHARMACEUTICALS INC | 82835W108 | COM | 4,012,903 | $17,295,612 | dollars as filed | |
| ALUMIS INC | 022307102 | COM | 1,959,896 | $14,483,631 | dollars as filed | |
| NKARTA INC | 65487U108 | COMMON STOCK | 3,333,333 | $8,733,333 | dollars as filed | |
| OCULIS HOLDING AG | H5870P102 | CMN | 641,022 | $5,987,146 | dollars as filed | |
| ULTRAGENYX PHARMACEUTICAL IN | 90400D108 | COM | 137,753 | $2,070,428 | dollars as filed | |
| ENGENE THERAPEUTICS INC | 29286X101 | COM | 747,750 | $1,495,500 | dollars as filed |
Amendment chain
| Filing | Role | Filed | Accepted | Ingested |
|---|---|---|---|---|
| 13F-HR 0001012975-26-001062 | this filing | 2026-11-16 |